Can a scopolamine transdermal patch cause nausea and vomiting?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Scopolamine Patch Cause Vomiting?

Yes, scopolamine transdermal patches can paradoxically cause nausea and vomiting, particularly as withdrawal symptoms after prolonged use or as part of gastrointestinal side effects related to delayed gastric emptying.

Direct Evidence from FDA Labeling

The FDA drug label explicitly lists nausea and vomiting as potential adverse effects of scopolamine patches in two distinct contexts 1:

Gastrointestinal Side Effects

  • Difficulties in food passing from the stomach to small intestines can occur, which may cause abdominal pain, nausea, or vomiting during active use
  • This represents an anticholinergic effect that slows gastric motility

Withdrawal Symptoms

  • After removing the patch following several days of use, patients may experience withdrawal symptoms including:
    • Nausea
    • Vomiting
    • Stomach cramps
    • Dizziness
    • Confusion
    • These symptoms can start 24 hours or more after patch removal
    • The FDA specifically warns to call your doctor if these withdrawal symptoms become severe 1

Clinical Context: Intended Use vs. Paradoxical Effects

While scopolamine is FDA-approved and guideline-recommended for preventing nausea and vomiting (from motion sickness and postoperative causes) 1, it can cause the very symptoms it's meant to prevent through:

  1. Anticholinergic effects on GI motility - slowing gastric emptying during active use
  2. Rebound effects - withdrawal phenomenon after discontinuation
  3. Individual susceptibility - some patients may experience paradoxical reactions

Evidence from Clinical Guidelines

The NCCN guidelines list scopolamine 1.5 mg transdermal patch as a breakthrough treatment option for chemotherapy-induced nausea/vomiting, applied every 72 hours 2. This indicates its primary role is antiemetic, but the FDA warnings about nausea/vomiting as side effects remain clinically relevant.

Key Clinical Pitfalls

Watch for these scenarios where scopolamine may worsen rather than improve symptoms:

  • Prolonged use beyond 3 days - increases risk of withdrawal symptoms upon removal
  • Patients with pre-existing gastroparesis or delayed gastric emptying - anticholinergic effects may worsen GI stasis
  • Abrupt discontinuation after extended use - plan for gradual weaning if used beyond several days
  • Elderly patients - more susceptible to anticholinergic side effects including confusion and GI disturbances 3

Bottom Line

If a patient develops nausea and vomiting while using or after discontinuing a scopolamine patch, consider the patch itself as a potential cause rather than assuming treatment failure. This is particularly important in the 24-72 hour window after patch removal, when withdrawal symptoms peak.

References

Guideline

nccn guidelines insights: antiemesis, version 2.2017.

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.